Latest Conference Content

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, previewed her presentation of extended follow-up data from the phase 3 ALPINE trial and other studies of interest to CLL specialists at the 2023 American Society of Hematology (ASH) Annual Meeting.

Sara Hurvitz, MD, FACP, shares insights into the results of the HER2CLIMB-02 trial, which saw patients with HER2-positive breast cancer benefit from the addition of tucatinib to trastuzumab emtansine (T-DM1).

The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.

Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.

A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”

Virginia Kaklamani, MD, previews sessions of interest and overviews what to look forward to heading into the San Antonio Breast Cancer Symposium (SABCS) 2023.

The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.

Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University's Feinberg School of Medicine, discussed type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Dr. Parth Rali, MD, of Temple University Hospital explained the challenges of managing patients with intermediate-risk pulmonary embolism (PE) and how risk stratification tools can help to address these challenges.

Kimberly Maxfield, PhD, of the FDA discussed actions been taken by the FDA since President Biden's reauthorization of the Biosimilar User Fee Act (BsUFA) III last year, as well as what they plan to achieve through 2027.

With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).

Amal Trivedi, MD, MPH, professor at Brown University, discusses the qualities that led him to nominate David J. Meyers, PhD, to receive the Seema S. Sonnad Emerging Leader in Managed Care Research Award. The American Journal of Managed Care® presented the award to Dr Meyers at the 2023 Patient-Centered Oncology Care® meeting.

Posters presented at ACAAI 2023 Annual Scientific Congress assessed digital health tools to improve asthma self-management.

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses.

The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, highlights the need for trust between payers and providers, as well as finding balance in building consistent clinical pathways while prioritizing specific practice needs.

There is a lot of noise in the health care system, and oncologists need to collaborate and decide on common shared goals, said Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare.

Leveraging technology intelligently can make the patient-doctor interaction much more seamless and connected, said Samyukta Mullangi, MD, MBA, medical director of oncology at Thyme Care, medical oncologist at Tennessee Oncology.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, lists barriers to care for dermatology patients.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.

There is great value, both for clinical trials and clinical practice, in biomarkers that identify patients at greatest risk of developing chronic kidney disease (CKD) after acute kidney injury, explained Steven Coca, DO, MS, Icahn School of Medicine at Mount Sinai.

Presenters at the American Society of Nephrology (ASN) Kidney Week 2023 highlighted the exciting new technologies that nephrology research has developed to improve patient outcomes, quality of life, and approaches to care.

Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.

The use of a bioartificial kidney could save the transplant population from a life of immunosuppression drugs and save costs, according to Shuvo Roy, PhD, professor of bioengineering at the University of California San Francisco.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.

Presenters at ASN Kidney Week 2023 emphasized the importance of patient education, awareness, and advocacy in the realm of kidney transplantation.

The annual Patient-Centered Oncology Care® (PCOC) meeting returns to Nashville, Tennessee, on November 7-8, bringing oncology stakeholders together for 2 days of discussions and presentations on the rapidly changing oncology care landscape.

For patients with chronic kidney disease, dose adjustments for other medications requires coordination with other specialists to maintain treatment efficacy, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.